NASDAQ:DMAC DiaMedica Therapeutics Q3 2026 Earnings Date & Estimates $9.48 -0.17 (-1.76%) As of 03:11 PM Eastern This is a fair market value price provided by Massive. Learn more. DiaMedica Therapeutics is scheduled to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for November 13, 2026 at 8:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call DateNovember 13, 2026Conference Call8:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from DiaMedica Therapeutics in Q3 2026DiaMedica Therapeutics is expected to post earnings of -$0.20 per share on revenue of $13.50 million. In the same quarter a year earlier DiaMedica Therapeutics reported -$0.17 per share. DiaMedica Therapeutics last reported on August 10, 2026, posting -$0.19 per share and beating the -$0.2009 consensus estimate. DiaMedica Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.20Expected Revenue$13.50 millionPrior-Year EPS-$0.17Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.19 (Beat by +$0.0109)EPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report DiaMedica Therapeutics Q3 2026 Earnings FAQ When does DiaMedica Therapeutics report Q3 2026 earnings? DiaMedica Therapeutics (NASDAQ:DMAC) has confirmed it will report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. What time is DiaMedica Therapeutics' Q3 2026 earnings call? DiaMedica Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for DiaMedica Therapeutics? Analysts expect DiaMedica Therapeutics to post earnings of -$0.20 per share for Q3 2026. How much revenue is DiaMedica Therapeutics expected to report? The consensus revenue estimate for DiaMedica Therapeutics is $13.50 million for Q3 2026. DiaMedica Therapeutics Earnings HeadlinesDiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026November 5, 2026 | finance.yahoo.comDiamedica Therapeutics (DMAC) AI Stock AnalysisNovember 2, 2026 | tipranks.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 10 at 1:00 AM | Behind the Markets (Ad)DiaMedica Therapeutics Inc. Announces Enrollment Of 200th Patient In Its Pivotal Phase 2/3 ReMEDy2 Trial Of DM199 In Acute Ischemic StrokeOctober 22, 2026 | marketscreener.comMDiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke TrialOctober 22, 2026 | finance.yahoo.comDiaMedica Therapeutics Reaches Patient Enrollment Milestone for Phase 2/3 Trial of DM199 in Acute Ischemic StrokeOctober 22, 2026 | finance.yahoo.comSee More DiaMedica Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DiaMedica Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaMedica Therapeutics and other key companies, straight to your email. Email Address About DiaMedica TherapeuticsDiaMedica Therapeutics (NASDAQ:DMAC) is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases affecting the kidneys and nervous system. The company’s research is centered on therapies intended to address conditions with limited treatment options. DiaMedica’s lead investigational product is DM199, a recombinant form of human tissue kallikrein-1, an enzyme involved in blood flow regulation and vascular function. The company has evaluated DM199 in clinical development programs targeting acute ischemic stroke and kidney-related diseases, including chronic kidney disease. DM199 is an investigational therapy and has not been approved for commercial use. Headquartered in Minneapolis, Minnesota, DiaMedica conducts its research and clinical development activities through collaborations and trials primarily involving the United States and other international markets. Rick Pauls serves as the company’s chief executive officer.View DiaMedica Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles D-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Microsoft’s Neocloud Pullback Isn’t a Crack in AI DemandOklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next? Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
